pharma · Achondroplasia · Amyloid Cardiomyopathy, Transthyretin-Related · BBOT
BridgeBio Oncology Therapeutics
BridgeBio Oncology Therapeutics patent portfolio — 1 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.
Company details
- Status
- Public
- HQ
- 256 E Grand Ave, Suite 104, South San Francisco, California 94080, US
- Employees
- 103
- Programs
- 34
- Drugs
- 14
- Patents
- 1
BridgeBio Oncology Therapeutics patents
1 pharmaceutical patents indexed for BridgeBio Oncology Therapeutics. 0 expire within 24 months.
BridgeBio Oncology Therapeutics has 1 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.
Patent portfolio
Frequently asked questions
How many patents does BridgeBio Oncology Therapeutics have?
1 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do BridgeBio Oncology Therapeutics patents expire?
0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.